Biden’s Abortion Strategy Omits Regulatory Changes That Could Boost Mifepristone Access

 
• By Brenda Sandburg

HHS report on protecting reproductive care shows administration is reluctant to take bold actions to counter Supreme Court’s Dobbs decision. Report does not suggest revising or eliminating mifepristone’s REMS or seeking preemption legal battles as some advocates have urged.

Abortion restriction
HHS does not propose how to overcome restrictions on abortion medication • Source: Shutterstock

More from US FDA

More from Agency Leadership